Is seizure prophylaxis recommended in intracerebral hemorrhage?

Seizure Prophylaxis in Intracerebral Hemorrhage

Routine seizure prophylaxis is NOT recommended for patients with spontaneous intracerebral hemorrhage (ICH). The evidence consistently demonstrates that prophylactic antiseizure medications (ASMs) do not prevent early or late seizures and may worsen functional outcomes 1, 2.

Key Evidence Against Routine Prophylaxis

The 2022 AHA/ASA guidelines explicitly state that prophylactic ASMs after spontaneous ICH:

• Do not prevent early seizures (within 14 days) 1
• Do not prevent late seizures (beyond 14 days) 1
• May worsen functional outcomes, particularly cognitive function 1
• Increase adverse events without mortality benefit 2

The most recent Neurocritical Care Society 2025 guideline reinforces this, suggesting avoidance of prophylactic ASMs in hospitalized adults with acute nontraumatic ICH (weak recommendation, very low quality evidence) 2.

When to Treat: Active Seizures Only

Treat only when seizures are clinically suspected or confirmed, not prophylactically 1. Specifically:

Indications for ASM Treatment:

• Witnessed clinical seizures at any time
• Impaired or fluctuating consciousness out of proportion to the degree of brain injury or metabolic abnormalities 1
• Confirmed electrographic seizures on continuous EEG monitoring 1

EEG Monitoring Strategy:

For patients with unexplained altered consciousness:

• Obtain continuous EEG for at least 24 hours 1
• For comatose patients, consider 48 hours of monitoring (94% of electrographic seizures detected by 48 hours vs. 72% at 24 hours) 1
• 28% of electrographic seizures occur after 24 hours of monitoring 1

If ASMs Are Used (Against Guideline Recommendations)

Some clinicians still use prophylaxis in select high-risk scenarios. If this approach is taken:

Agent Selection:

Use levetiracetam over phenytoin/fosphenytoin 2

• Phenytoin is associated with worse outcomes in older studies 1
• Levetiracetam shows trend toward better outcomes, though not statistically significant 1
• Recent network meta-analysis suggests valproate may have best efficacy/safety profile, though this requires further validation 3

Duration:

Limit to ≤7 days maximum if prophylaxis is used 2

• Longer duration does not prevent late seizures 1
• Quality-adjusted life-years are increased with shorter duration 2
• Risk scores (e.g., CAVE score) should NOT guide continuation of ASMs beyond acute period 1

Critical Pitfalls to Avoid

1. Do not use prophylactic ASMs routinely - this is the most common error and contradicts current guidelines 1, 2

2. Do not continue ASMs long-term without documented seizures - no evidence supports late seizure prevention 1, 2

3. Do not assume altered consciousness equals seizures - obtain EEG confirmation before treating 1

4. Do not use phenytoin if ASMs are needed - associated with worse outcomes in ICH specifically 1

5. Do not rely on risk stratification scores to justify prophylaxis - CAVE score can estimate risk but should not guide prophylactic treatment 1

High-Risk Subgroups (Still No Proven Benefit)

While these patients have higher seizure risk, prophylaxis remains unproven even in:

• Lobar hemorrhages (cortical proximity) 4
• Patients undergoing surgical evacuation 4
• Poor-grade patients with thick cisternal blood (more relevant for SAH) 5

These characteristics may lower the threshold for EEG monitoring but do not justify routine prophylaxis 1.

The Bottom Line Algorithm

1. No clinical or electrographic seizures → No ASMs 1, 2

2. Unexplained altered consciousness → Continuous EEG for 24-48 hours 1

3. Confirmed seizures (clinical or electrographic) → Treat with levetiracetam 2

4. If prophylaxis used despite guidelines → Levetiracetam ≤7 days only 2

5. No documented seizures after acute period → Discontinue ASMs 1, 2